RESUMO
Trichoblastoma (TB) is a benign cutaneous adnexal neoplasm. The lesion typically presents as a slow-growing, solitary, well-circumscribed nodule measuring up to 3 cm in diameter. On rare occasions, TB causes malignant transformation into an aggressive form described as high-grade trichoblastic carcinoma. Four such cases have been reported to date; all were described as high-grade trichoblastic carcinomas. Here, we describe the case of a 72-year-old Japanese male patient with a rapidly enlarging subcutaneous tumor on his lower back, which was diagnosed as high-grade trichoblastic carcinoma. Histopathologically, the tumor featured both benign and malignant components, and a transition zone between these states was clearly evident. In the immunohistochemical analysis, a malignant component was positive for p53 and showed stronger staining of phospho-RAC-α serine/threonine-protein kinase (AKT) Ser473 in comparison with a benign component. These results suggest that loss of p53 function and activation of phosphatidylinositol 3-kinase-AKT signaling pathways played important pathogenic roles in malignant transformation of the present case.
Assuntos
Carcinoma de Apêndice Cutâneo/patologia , Transformação Celular Neoplásica/patologia , Doenças do Cabelo/patologia , Neoplasias Cutâneas/patologia , Idoso , Carcinoma de Apêndice Cutâneo/diagnóstico por imagem , Carcinoma de Apêndice Cutâneo/cirurgia , Doenças do Cabelo/diagnóstico por imagem , Doenças do Cabelo/cirurgia , Folículo Piloso/patologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Fosforilação , Proteínas Proto-Oncogênicas c-akt/metabolismo , Neoplasias Cutâneas/diagnóstico por imagem , Neoplasias Cutâneas/cirurgia , Resultado do Tratamento , Proteína Supressora de Tumor p53/metabolismoAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Docetaxel/uso terapêutico , Ácido Oxônico/uso terapêutico , Doença de Paget Extramamária/terapia , Tegafur/uso terapêutico , Adenocarcinoma de Pulmão/diagnóstico por imagem , Adenocarcinoma de Pulmão/terapia , Idoso , Quimioterapia Adjuvante/métodos , Combinação de Medicamentos , Humanos , Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/terapia , Masculino , Doença de Paget Extramamária/diagnóstico por imagem , Pneumonectomia , Tomografia por Emissão de Pósitrons , Neoplasias Cutâneas/diagnóstico por imagem , Neoplasias Cutâneas/terapia , Resultado do TratamentoRESUMO
Dehydroxymethylepoxyquinomicin (DHMEQ, 1) is a novel nuclear factor-kappaB (NF-kappaB) inhibitor that inhibits DNA binding of NF-kappaB components including p65. To inspect its biological activity of 1, we synthesized parasitenone (3), possessing the common epoxycyclohexenone moiety of 1. Assessment of the inhibitory activity against NF-kappaB indicated that the epoxycyclohexenone moiety is the most essential element for the NF-kappaB inhibitory activity and the salicylic acid moiety may contribute the binding efficiency and specificity.